Offshore generics makers eye biosimilars

Chinese and Indian generics makers say they are on the verge of selling cheaper copies of complex biotech medicines. They may enter the market as soon as next year, thanks to huge investments in biotech plants. The New York Times anticipates a transformation of care for patients in much of the world in addition to a counterattack by Big Pharma. Story

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.